

## PHARM.D. FELLO\\/SHIP



in	
X	
A	
D	



Why Daiichi Sankyo?
Company Overview3
• A Legacy of Innovation Since 18994
Company at a Glance4
Values & Behaviors  5
A Message from Our U.S. President6
How WeTHRIVE
Why This Mid-Sized Company?8
• The Fellowship Experience9
Past Fellow Perspectives10
• Fellowship Alumni11
• Fellowship Steering Committee
Co-Chief Fellows13
• Fellow Committee Leads14
Recruiting Fellowships15
Clinical Science (CS)     One, 2-Year Position
<ul> <li>Global Clinical Safety &amp; Pharmacovigilance (GCSPV)</li></ul>
<ul> <li>Global Oncology Marketing (GOM)</li></ul>
<ul> <li>Global Oncology Medical Affairs (GOMA)</li></ul>
<ul> <li>Global Regulatory Labeling Strategy (GRLS)</li></ul>
• U.S. Marketing Fellowship (USM)
• U.S. Medical Affairs (USMA)
<ul> <li>U.S. Oncology Business Division         Training &amp; Development (OBD T&amp;D)</li></ul>

Non-Recruiting Fellowships46
Companion Diagnostics (CDx)47
Global Business Development (GBD)     Transactions & Marketing
Global Oncology Value, Access & Pricing (GOVAP)49
Global Regulatory Affairs (GRA)50
Pharmacoepidemiology (PE)
Quality Assurance Good Manufacturing Practices (QA GMP)
Quantitative Clinical Pharmacology (QCP)53
• Translational Science (TS)54
Rutgers Pharmaceutical
Industry Fellowship (RPIF)55
• Leadership56
• Program History & Professional Development Series57
Key Program Features & Application     Process and Eligibility Requirements
RPIF Chief Fellow Perspectives





## Company Overview



#### Our Vision: To Be an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society

At Daiichi Sankyo, we create essential medicine for longer, better lives. Every day, we strive to put our skills at the service of those in need. We unite cutting-edge science and technology with unwavering dedication and care to develop life-changing solutions for our patients.

We rely on reason, ingenuity, perseverance, and empathy to make bold strides in oncology and will continually rise to the challenges ahead.

We owe our success to the collaboration between our people, scientists, healthcare providers and advocates. Thanks to their passionate expertise, they are all essential partners on our journey. Building on our 125-year-old heritage and a culture of innovation and inclusion, our 18,500+ employees are forging better futures through medicine for people everywhere.

Together, we are creating new standards of care—our contribution to the enrichment of quality of life around the world.

Please visit DaiichiSankyo.us for U.S.-specific information, or DaiichiSankyo.com for a global view.



## A Legacy of Innovation Since 1899

#### Recognized Leader in **Medicine for Over a Century**

Our heritage of scientific discovery spans since 1899 – from the discovery of epinephrine (adrenaline) and the development of the statin class of lipid-lowering agents to the development of the first glitazone that revolutionized long-term control of type 2 diabetes.

Our parent company, Daiichi Sankyo Co., Ltd., was established in 2005 with the merger of two leading centuryold pharmaceutical companies, Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. Headquartered in Tokyo, the company is dedicated to the creation and supply of innovative pharmaceutical products that address the unmet medical needs of patients in mature and emerging markets. Today, our products help patients in over 20 countries/regions around the world, including North America, Japan, Asia, Latin America and Europe.

#### Our Legacy in the U.S.

The thousands of cherry trees that line the tidal basin in West Potomac Park in Washington, D.C. aren't a natural phenomenon. They represent a cross-cultural partnership between the United States and Japan that was forged over 100 years ago.

In 1912, world-famous chemist and our company's first president, Dr. Jokichi Takamine gifted 3,000 cherry trees from Mayor Yukio Ozaki of Tokyo to the city of Washington, D.C. as a symbol of harmony between our two nations.

U.S. subsidiary Daiichi Sankyo, Inc., began operating in the U.S. in 2006 as a member of the Daiichi Sankyo Group. Not only is the gift an important symbol of global collaboration, but it is an important part of our history and Dr. Takamine's legacy, whose collaborative role continues to inspire our company today.



## AT A GLANCE COMPANY

A Legacy of Innovation since

1899

19.7K+

Global **Employees** 

2,600+

U.S. Employees 48

**Group Companies** 

32

Country and Area Presence

¥1,886.3B

FY24 Consolidated Global Revenue

13

Production & Manufacturing sites

22

**R&D** Locations







#### Dalichi-Sanhyo PHARM.D. FELLOWSHIP

## Values & Behaviors

Daiichi Sankyo's core values and behaviors are the guiding principles that direct decision-making.
They speak to what is important to the organization and the individuals, along with what patients, customers and employees can expect.

#### **Core Values**

#### Innovation

The introduction of new ideas, methods, or invention

#### Integrity

The quality of being honest and of always having high moral principles

#### Accountability

Being responsible for the effects of your actions, and being willing to explain or be criticized for them





#### **Core Behaviors**

#### Be Inclusive & Embrace Diversity

We value people for who they are as individuals, and welcome diverse perspectives in our work, which enables us to achieve more as Daiichi Sankyo

#### Collaborate & Trust

We treat each other with respect and build trust through transparency and willingness to listen, which enables us to collaborate simply and productively

#### Develop & Grow

We learn, experiment, and take initiative, which enables us to grow together every day and strengthen Daiichi Sankyo's capability









# A Message from Our U.S. President

Daiichi Sankyo is a unique, global organization that has a rich history of innovation, research and discovery. As our people embrace challenges, we support them in seeking new opportunities and growing their careers. Fellows thrive in the culture we have built at Daiichi Sankyo and begin contributing to our mission, to bring new, meaningful medicines to the world, from day one. ? ?

#### Ken Keller

Global Head, Oncology Business President & CEO, Daiichi Sankyo, Inc.











## HOW WE THREE At Dailchi Sankyo, we believe in the power of well-being: embrace and take advantage!


WeTHRIVE evolves our ways of working, improves work-life harmony and has become a key element of our culture.

#### Why WeTHRIVE?

WeTHRIVE began company wide in 2021 and is one reflection of leadership's commitment to the well-being of employees. Being our best for patients starts with taking care of our own well-being. While there's no magic approach to doing this, there are small steps we can all take together that can make a big impact.

#### **Empowering Employees to Thrive**

WeTHRIVE is a fundamental part of our culture where employees are accountable for actively engaging in their well-being, fostering work-life harmony, and utilizing provided resources to create a supportive environment where everyone's well-being is valued and prioritized.



<sup>\*</sup>Applies to all non-field-based employees





<sup>\*\*</sup>Does not apply to field employees—field employees have July 4 De-Stressor Week



## Why This Mid-Sized Company?



At Daiichi Sankyo, Inc., our people are our greatest asset and by investing in inclusive practices across the organization we firmly believe we are able to bring the best medicines to our patients.

- Individualized experience aligned with fellows' interests
- Broad support throughout the organization
- Close interactions with high-level management and peers
- Many opportunities to lead, rotate and/or assist with projects in various areas of the business to gain exposure to different areas of the pharmaceutical industry
- Open and approachable leaders
- Comfortable, flexible and supportive work environment



## The Fellowship Experience

#### Promising New Compounds

More than 35 products currently in our pipeline in diverse therapeutic areas



## Profe Fellows are help expan

#### Professional Connections

Fellows are integrated into project teams which help expand their professional network

#### 108 Fellowship Alumni\*

Unique and valuable hands-on experience for every fellow





#### Global Mid-sized Company

Provides products in over 32 countries/regions and encompasses over 19.7K+ employees worldwide



Areas of focus include oncology and specialty therapeutics







#### Leadership Potential

Fellows plan and execute strategy and tactics by leading projects, presentations and meetings cross-functionally

#### Track Record of Innovation

Heritage of scientific discovery spans a legacy of innovation since 1899 from the discovery of epinephrine to the development of the first statin and now industry leader in ADC development





#### Diverse Career Opportunities

Fellows have crossed into different functional areas both during and after the program





#### **FELLOWSHIP**

#### Past Fellow Perspectives

**TAKEAWAYS** 



- Real-world experiential learning led by knowledgeable mentors
- Grow as a leader by tackling complex projects

Anthony Mack, Pharm.D., M.Sc. 2022-2024 Clinical Science Fellow University of Michigan College of Pharmacy



- Unwavering senior leadership support
- Contribute to key impactful deliverables

Claire Groce, Pharm.D. 2023-2025 Global Oncology Medical Affairs Fellow

Mercer University College of Pharmacy



- Culture of mentorship and growth
- Opportunity to make key contributions

Brittany Tran, Pharm.D. 2021-2023 Quantitative Clinical

Pharmacology Fellow

University of the Pacific, Thomas J. Long School of Pharmacy



- Deliver results through patient-centered projects
- Collaborate across to build critical thinking and adaptability

Jill Desai, Pharm.D., M.B.A.

2020-2022 Global Marketing Research & Insights Fellow

Rutgers University, Ernest Mario School of Pharmacy



- Company culture that values integrity and accountability
- Meaningful projects that promote patient interests

Juhi Hegde, Pharm.D., R.Ph. 2023-2025 Clinical Safety & Pharmacovigilance Notre Dame of Maryland University School of Pharmacy

#### EN $\alpha$ Ш 1 X

Succeeding in the pharma industry entails more than possessing scientific expertise - it requires proficiency in collaborative team-work, effective communication and an aptitude for adapting to new and evolving industry trends.

Engage in comprehensive hands-on experience

Work alongside industry experts and thought leaders

Apply the skills acquired during their pharmacy school training

**Preceptors** and mentors provide a supportive learning environment

Acquire a competitive edge in the pharmaceutical industry





A

#### **FELLOWSHIP**

#### Fellowship Alumni

Christina N. Breen, Pharm.D. Medical Affairs (2001-2002)

Amy Desai, Pharm.D.

Medical Affairs (2002-2003)

Christine L. Racchini, Pharm.D. Scientific Affairs (2002-2003)

Brad F. Tumminello, Pharm.D. Medical Affairs (2003-2004)

Gina L. Vestea, Pharm.D. Scientific Affairs (2003-2004)

Giby Thomas, Pharm.D. Medical Affairs (2004-2005)

Mahesh Tawney, Pharm.D. Scientific Affairs (2004-2005)

Theresa D. Ankamah, Pharm.D. Medical Affairs (2005-2006)

Nana K. Wiafe-Ababio, Pharm.D. Scientific Affairs (2005-2006)

Jessa Ford Depew, Pharm.D. Medical Affairs (2006-2007)

Chhaya Patel, Pharm.D. Medical Affairs (2006-2007)

BoYoung Goh, Pharm.D. Medical Affairs (2007-2008)

Jalpa Patel, Pharm.D. Medical Affairs (2007-2008)

Matthew Wong, Pharm.D. Medical Affairs (2008-2009)

Nisha Patel, Pharm.D. Medical Affairs (2008-2009)

Neil Mattai. Pharm.D. New Product Market Research (2008-2009)

Dominic Lai, Pharm.D. Medical Affairs (2009-2010)

Maninee Patel, Pharm.D.

Medical Affairs (2009-2010)

Irene Wang, Pharm.D. Medical Affairs (2010-2011)

Dipam Doshi, Pharm.D. Medical Affairs (2010-2011)

Ashley S. Johnson, Pharm.D. Medical Affairs (2010-2011)

Michelle Lee. Pharm.D. Medical Affairs (2011-2012) Amee Patel, Pharm.D.

Medical Affairs (2011-2012)

Nupur Patel, Pharm.D. Medical Affairs (2011-2012)

Ruth Haile-Meskale, Pharm.D., M.B.A. Medical Affairs (2012-2013)

Eric Zhao, Pharm.D. Medical Affairs (2012-2013)

Monica Sukhatme, Pharm.D.

New Product Business Analytics (2011-2013)

Poonam Fredeman, Pharm.D. Medical Affairs (2012-2014)

Jacob Reichert, Pharm.D. Medical Affairs (2013-2015)

Chrissie Chew, Pharm.D. Medical Affairs (2013-2015)

Benjit Singh, Pharm.D. Commercial, New Product Planning (2013-2015)

Sarah Kwon, Pharm.D., M.B.A.

Marketing Sciences (2013-2015) Nilomi Shah, Pharm.D. Medical Affairs (2014-2016)

Alexander Oladele, Pharm.D., R.Ph. Medical Affairs (2015-2017)

Gediminas Pliura, Pharm.D., R.Ph. Commercial, New Product Planning (2015-2017)

Bridget McGugan, Pharm.D., M.B.A. Commercial, Market Research Oncology (2016-2018)

Alyson Sapirstein, Pharm.D., R.Ph., M.B.A. Commercial, Global Oncology Marketing (2017-2019)

Bridgette Tran. Pharm.D., R.Ph. U.S. Medical Affairs (2017-2019)

Lukasz Jarosz. Pharm.D. Global Business Development -Transactions (2018-2020)

Joshua Lin, Pharm.D., R.Ph. U.S. Medical Affairs (2018-2020)

Harsh Reddy, Pharm.D., R.Ph. Global Oncology Marketing (2018-2020)

Omama Zubairi, Pharm.D. Global Medical Affairs, Oncology (2018-2020)

Samantha Breckenridge, Pharm.D. U.S. Medical Affairs (2019-2021)

Haeyon Lee, Pharm.D.

U.S. Medical Affairs (2019–2021)

Rohan Chittella, Pharm.D. Commercial (2019-2021)

Nikhil Dondapati, Pharm.D. Commercial (2019-2021)

Mackenzie Henderson, Pharm.D., R.Ph. Pharmacoepidemiology (2019–2021)

Alexander Huelsman, Pharm.D., R.Ph. U.S. Medical Affairs (2020-2022)

Joseph Cheng, Pharm.D. U.S. Medical Affairs (2020-2022)

Alberta Drake, Pharm.D., R.Ph. Global Oncology Market Research (2020-2022)

Jill Desai, Pharm.D., R.Ph. Global Oncology Market Research & Insights (2020-2022)

Eric Wang, Pharm.D. Pharmacoepidemiology (2020-2022)

Cindy Li, Pharm.D.

Clinical Development (2020-2022)

Elizabeth Booth, Pharm.D., R.Ph. Quantitative Clinical Pharmacology (2020-2022)

Andrew Perez-Viñas, Pharm.D., M.B.A. U.S. Medical Affairs (2021-2023)

Brigitte Azzi, Pharm.D.

U.S. Medical Affairs (2021-2023)

Morgan Bowling, Pharm.D. Global Oncology Medical Affairs (2021-2023)

Samantha Wilusz, Pharm.D.

Global Oncology Medical Affairs (2021-2023)

Michael Obineme, Pharm.D., R.Ph. Global Business Strategy & Analytics (2021-2023)

Gregory Waldek, Pharm.D., R.Ph. Global Business Strategy & Analytics (2021-2023)

Mohamed Kashkoush, Pharm.D., R.Ph. Global Business Development (2021-2023)

Priyanka Yalamanchili, Pharm.D., R.Ph.

Pharmacoepidemiology (2021-2023) Aaron Tocker, Pharm.D.

Clinical Science (2021-2023)

Thi Nguyen, Pharm.D., R.Ph. Clinical Science (2021-2023)

Brittany Tran, Pharm.D. Quantitative Clinical Pharmacology (2021-2023) Youngjun Yoo, Pharm.D., R.Ph.

Quantitative Clinical Pharmacology (2021-2023)

Timothy Hajj Jr. Pharm.D. Global Regulatory Affairs (2021-2023)

Rohan Vashi, Pharm.D. Global Health Economics & Outcomes Research (2021-2023)

Jessica Maruca, Pharm.D. Clinical Science (2022-2024)

Anna Wise, Pharm.D. Clinical Science (2022-2024)

Anthony Mack, Pharm.D. Clinical Science (2022-2024)

Lindsay Ratner, Pharm.D. Companion Diagnostics (2022-2024)

Jenna Park, Pharm.D. Companion Diagnostics (2022-2024)

Kaide Udit. Pharm.D.

Global Clinical Operations (2022-2024)

Eliana Maia-Goldstein, Pharm.D. Quantitative Clinical Pharmacology (2022-2024)

Alexander Yu, Pharm.D.

Quantitative Clinical Pharmacology (2022-2024)

Pooja Vekaria, Pharm.D. Regulatory Affairs (2022-2024)

Shafat Selim, Pharm.D. Business Strategy & Analytics (2022-2024)

Madison Henry, Pharm.D. Global Oncology Medical Affairs (2022-2024)

Kyle Taylor, Pharm.D. Global Oncology Medical Affairs (2022-2024)

Nikhil Mohan, Pharm.D.

U.S. Medical Affairs (2022-2024)

Thanh Mai. Pharm.D. U.S. Medical Affairs (2022-2024)

Timothy Choi, Pharm.D. CSPV (2022-2024)

Chaeyun Lee, Pharm.D. CSPV (2022-2024)

Oluwatosin Fofah. Pharm.D. Pharmacoepidemiology (2022-2024)

Amira Geris. Pharm.D. Clinical Science (2023-2025)

Chinh Kieu, Pharm.D. Clinical Science (2023-2025) Yash Patel, Pharm.D.

Clinical Science (2023-2025)

Elizabeth Barton, Pharm.D. Clinical Science (2023-2025)

Chloe Koo, Pharm.D.

Quantitative Clinical Pharmacology (2023-2025)

Jahmal Williams, Pharm.D. Global Oncology Medical Affairs (2023-2025)

Claire Groce, Pharm.D.

Global Oncology Medical Affairs (2023-2025)

Starr Vang, Pharm.D. Global Clinical Operations & Planning (2023-2025)

Candice Drinkwater, Pharm.D. Pharmacoepidemiology (2023-2025)

Alyssa Dempsey, Pharm.D. U.S. Medical Affairs (2023-2025)

Yoo Meen Suh, Pharm.D. U.S. Medical Affairs - MI&E (2023-2025)

Ryan Friedrich, Pharm.D. Business Strategy & Analytics (2023-2025)

Joon Lee, Pharm.D.

Global Business Development (2023-2025) Mu Qiu. Pharm.D.

Business Strategy & Analytics (2023-2025)

Sheena Licata, Pharm.D. US Marketing (2023-2025)

Kajal Rana, Pharm.D. US Marketing (2023-2025)

Juhi Hegde, Pharm.D. CSPV (2023-2025) Simrun Lakhani, Pharm.D.

CSPV (2023-2025)

Khushbu Patel, Pharm.D. Global Oncology Value, Access & Pricing (2023-2025)

Sarah Park, Pharm.D. Global HEOR (2023-2025)

Libby Shelton, Pharm.D. **OBD Training & Development** (2023-2025)

Sarayu Anmangandla, Pharm.D. Translational Science (2023-2025)

Victor Gazdoiu, Pharm.D. Companion Diagnostics (2023-2025)







## Fellowship Steering Committee

The Daiichi Sankyo Fellowship Steering Committee will contribute to program strategy and direction with the goals of fostering professional and personal growth, engaging all stakeholders, and **retaining** the developed talent.





**Kimberly Small** Associate Director, Early Career Talent Programs **HUMAN RESOURCES** 

EXECUTIVE SPONSORS



Tamy Recchia, Pharm.D. Executive Director. USMA Innovation and Excellence

**U.S. MEDICAL AFFAIRS** 



Malaz Abu-Tarif, Ph.D., M.B.A. Vice President, Global Quantitative Clinical Pharmacology **QCP** 

**CO-CHIEF FELLOWS** 



Jacqueline Conti, Pharm.D., R.Ph. Second-Year Fellow **CLINICAL SCIENCE** 



Sara Blodgett, Pharm.D., R.Ph. Second-Year Fellow **REGULATORY AFFAIRS** 





Kristin Vaneekhoven, Pharm.D. Senior Director, Head of Oncology Global Medical Content & Training **GLOBAL ONCOLOGY MEDICAL AFFAIRS** 



Susan Lee, Pharm.D. Associate Director. Oncology Access & Market Dynamics Training **U.S. BUSINESS OPERATIONS** 



Jill Desai, Pharm.D. Associate Director. Global Brand Strategy **GLOBAL ONCOLOGY MARKETING** 



Mackenzie Henderson, Pharm.D. Associate Director, **PHARMACOEPIDEMIOLOGY** 



Kendall Sullivan, Pharm.D. Director, Clinical Science **CLINICAL SCIENCE** 













## AS CO-CHIEF FELLOVS, WE...

work with the Fellowship Steering Committee (FSC) to drive program strategy and implement deliverables that enhance fellows' personal and professional development. We also serve as the point of contact between RPIF leadership and Daiichi Sankyo fellows, liaise between the FSC and fellows, support the committee leads, and lead bi-weekly fellowship meetings.

Jacqueline Conti, Pharm.D., R.Ph.

Second-Year Fellow Clinical Science

Sara Blodgett, Pharm.D., R.Ph.

Second-Year Fellow Regulatory Affairs



### Fellowship Committee Leads

**MARKETING** 



Sophie Wei Pharm.D., R.Ph.

Oversees the development of the RPIF / Daiichi Sankyo Pharm.D. Fellowship Program brochure and communicates quarterly updates on the fellowship via the company-wide newsletter



#### RECRUITMENT



Ethan Lim Pharm.D.



**Sophia Ventrano** Pharm.D.

Develops RPIF / Daiichi Sankyo's recruitment strategy while quiding fellows and stakeholders throughout recruitment, including structuring candidate interviews, on-site touch points and ASHP Midvear.



#### **ALUMNI RELATIONS**



**Matthew Armanus** Pharm.D., M.B.A., R.Ph.

Head early efforts to build the Pharm.D. fellow alumni community at Daiichi Sankyo and promote engagement with the Company's Fellowship Program through hosting Lunch & Learns, guest speaker events and other networking activities



#### **EXTERNAL ENGAGEMENT**



**Rachel Clark** Pharm.D., R.Ph.

Coordinates externally facing Daiichi Sankyo fellowship events, including participation in RPIF FIND and Daiichi Sankyo Fellowship Reception



#### **FELLOW ENGAGEMENT**



Eileen Zheng Pharm.D.

Plans internal activities for fellows with the purpose of developing strong interprofessional relationships and promoting a positive, strong company culture















Clinical Science (CS): One, 2-Year Position	16
• Global Clinical Safety & Pharmacovigilance (GCSPV): Two, 2-Year Positions	20
Global Oncology Marketing (GOM): One, 2-Year Position	24
Global Oncology Medical Affairs (GOMA): Two, 2-Year Positions	27
Global Regulatory Labeling Strategy (GRLS): One, 2-Year Position	31
• U.S. Marketing Fellowship (USM): Two, 2-Year Positions	34
• U.S. Medical Affairs (USMA): One, 2-Year Position	38
• U.S. Oncology Business Division Training & Development (OBD T&D): One, 2-Year Position	42





The Clinical Science Fellowship Program offers the opportunity for the fellow to learn about how an oncology product moves through different stages of clinical development in its life cycle. This unique experience offered at Daiichi Sankyo provides the fellow with hands-on experience of learning about and contributing to early phase I to late phase III clinical trials of cutting-edge compounds in the oncology therapeutic area.

This two-year program will focus on the antibody drug conjugate (ADC) franchise and other compounds that span across multiple tumor types. The aim of the fellowship is to provide the necessary tools for the fellow to be able to design and manage clinical trials, provide input to the strategic decisions that optimize the study conduct, and lead tactics that support individual clinical trials and the program as a whole. The fellow will have close collaboration with other functional areas such as Clinical Operations, Project Management, Regulatory Affairs, and many other groups at Daiichi Sankyo.





#### CS Fellowship Activities & Experiences

#### Responsibilities

#### The main responsibilities of Clinical Science fellows include:

- Assist the clinical study team in protocol writing and amendments
- Conduct literature searches to support clinical decisions on study-level and program-level work
- Conduct clinical review of study data
- Interact with vendors that support the clinical trials and ensure timely delivery of work
- Contribute to project level work for the Clinical Science Department
- Engage KEEs (Key External Expert) and Primary Investigators in site initiation visits, investigator meetings, and conferences
- Assist in the preparation of scientific material for use in internal and external forums
- Engage in strategic discussions regarding study design based on evolving competitive and regulatory landscape

#### Interactions

In addition to oncology researchers and third party investigators, it is expected that fellows will interact with other functions particularly:

- Clinical Development
- Clinical Operations
- Medical Affairs
- Companion Diagnostics
- Clinical Safety
- Data Management
- Project Management
- Regulatory Affairs
- Biostatistics
- Commercial
- Clinical Pharmacology
- Translational Science

#### Requirements

#### It is expected that fellows will have:

- Analytical and organizational skills
- Oral and written communication skills
- Scientific writing skills
- Ability to work independently and collaboratively with a team
- Leadership and delegation skills
- High ethical behavior and integrity



#### CS Current Fellow Perspectives



- Meaningful core values and behaviors
- Commitment to sustainability, science, and patients
- Hands-on experience with promising ADC franchise

#### Eileen Zheng, Pharm.D.

Second-Year Fellow, Clinical Science University of Maryland School of Pharmacy



- Supportive mentorship
- Strong company ethics
- Leaders in oncology research and therapeutics

#### Jacqueline Conti, Pharm.D., R.Ph.

Second-Year Fellow, Clinical Science

The Ohio State University College of Pharmacy



- Visibility with senior leadership
- Supportive mentorship culture
- Exciting ADC pipeline

#### Jatin Jain, Pharm.D.

Second-Year Fellow, Clinical Science

Rutgers University, Ernest Mario School of Pharmacy



- Supported with unique opportunities and experiences
- Strong oncology pipeline to address unmet medical needs
- Meaningful employee core values reflected on patients world-wide

#### Engy Dous, Pharm.D.

First-Year Fellow, Clinical Science Long Island University, Arnold & Marie Schwartz College of Pharmacy



- Commitment to transforming oncology treatment landscape
- Collaborative environment focused on advancing innovative therapeutics
- Dedication to sustainability and global health

#### Maya Patel, Pharm.D.

First-Year Fellow, Clinical Science University of Florida College of Pharmacy



- Emphasis on leadership development
- Expanding and innovative oncology pipeline
- Meaningful and patient-centric company values

#### Andrew Phan, Pharm.D.

First-Year Fellow, Clinical Science University of the Pacific, Thomas J. Long School of Pharmacy

#### CS Fellowship Leadership Insights



Gain experience across functions in an innovative global healthcare company

Support development of novel therapeutics for patients

Join large network of fellows and build network with other professionals

Learn from experienced mentors and cross-functional leaders in the pharmaceutical industry

Contribute to a collaborative, forward-thinking environment that is shaping the future of oncology

Stephen Letrent, Pharm.D., Ph.D., M.B.A.

Vice President, Global Head Clinical Science



Hands-on industry experience in clinical development, bridging academic knowledge with real-world application

Accelerated career development through structured mentorship and training

Broad cross-functional exposure to clinical operations, regulatory, medical affairs, pharmacovigilance, and biostatistics

Opportunity to contribute meaningfully to clinical trials and scientific decision-making

Enhanced understanding of clinical trial design/execution from early-phase to registrational studies

Marina Youssef, Pharm.D., R.Ph, M.B.A.

Director, Clinical Science | Preceptor











Two, 2-Year Positions

GCSPV's vision is to put patients first by leading proactive safety surveillance and risk management to ensure quality and compliance throughout product life cycles. This is in line with Daiichi Sankyo's mission to create innovative pharmaceuticals to address diverse medical needs.

The GCSPV Fellowship provides the fellow with a comprehensive clinical safety experience within the Antibody Drug Conjugate (ADC) franchise/ Alpha products in the Oncology therapeutic area, to prepare the fellow for a career in clinical safety and pharmacovigilance. The fellow will be fully immersed in clinical safety aspects of product development activities, defining and performing safety monitoring and risk mitigation activities, communication plans to internal and external stakeholders, regulatory submissions, post-submission health authority queries, and post-marketing safety surveillance. The fellow will be closely collaborating with global and cross functional teams, such as Clinical Development and Regulatory Affairs. As part of this experience, the fellow will also have the opportunity to rotate through various departments at Daiichi Sankyo in the second year of the fellowship.





#### GCSPV Fellowship Activities & Experiences

#### Responsibilities

The key responsibilities and projects vary depending on the GCSPV area and include:

#### Signal Identification & Evaluation

- Learn and apply signal identification and evaluation techniques
- Assist Clinical Safety (CS) physicians in assessing new signals and tracking signals
- Analyze safety data from multiple sources (e.g., clinical, post-marketing, literature, etc.) to deliver comprehensive evaluations
- Gather competitive intelligence on safety information on other medications in class
- Collaborate with the Pharmacoepidemiology department to generate and/or evaluate realworld data in support of benefit-risk assessment
- Serve as a project manager for multidisciplinary Safety Management Team (SMT) discussions on emerging safety issues

#### Risk Management & Safety Strategy

- Collaborate cross-functionally with global colleagues and scientists, representing diverse backgrounds, knowledge, and expertise
- Participate in developing Risk Management Plans (RMP) and Risk Evaluation and Mitigation Strategies (REMS)
- Identify gaps in safety surveillance plans/RMPs and escalate appropriately
- Participate in creating appropriate risk minimization activities for assigned products with CS physician
- Participate in creating strategies for communicating important safety information internally and externally with CS physician
- Support CS physician in developing key documents (i.e. clinical study protocols, Investigator's Brochure, Core Data Sheet, informed consent forms, safety documents for regulatory submissions)
- Support ongoing safety monitoring and trends of safety data for clinical studies and post-marketing and support other functions in safety data generation
- Demonstrate familiarity with the Guideline on Good PV Practices and FDA Guidance related to clinical safety and post-marketing
- Prepare and present poster/abstracts/ scientific papers as well as attend national scientific conferences, FDA meetings, and KEE meetings

#### **Translational** Safety

- Develop translational research strategy for key safety issues, in collaboration with clinical safety and non-clinical toxicology teams
- Lead translational research project(s) aimed to address key drug safety issues, such as mechanism of toxicity and identification of high-risk patients
- External intelligence collection on the drug safety issues and their mechanisms

#### Rotations

#### Rotational Component:

Within the second year of the fellowship, each fellow will have the opportunity to rotate (3-6 months) through various departments at Daiichi Sankvo, dependent on a fellow's level of interest, availability of mentors, and/or projects with a high priority level within the organization

#### Rotations include:

- Clinical Development
- Regulatory **Affairs**
- Pharmacoepidemiology
- Medical Affairs
- Proiect Management & Leadership
- Translational Safety

#### Interactions

#### GCSPV interacts daily with stakeholders.

#### Internal stakeholders include:

- Global Clinical Development & Operations
- Global Regulatory Affairs & Regulatory Management Ops
- PV Operations and Pharmacoepidemiology
- Biostatistics & Data Management
- Quantitative Clinical Pharmacology
- Global Oncology Medical Affairs
- Global Project Management & Leadership
- Legal & Corporate Affairs

#### External stakeholders include (examples):

- Healthcare Professionals and Investigators including those at Clinical Trial Sites (Physicians, Nurses. Pharmacists)
- Vendors (CROs. AROs. Central Laboratories)
- Health Authorities (FDA, PMDA, CFDA, EMA, MHRA)
- Professional Societies (DIA, PMI, RAPS, ASCO. ESMO, ASH, EHA)

#### Requirements

#### It is expected that fellows will have:

- Drive for excellence and be self-motivated
- Excellent oral and written communication skills
- Highly ethical behavior and integrity
- Ability to work independently and collaboratively with others
- Scientific inquisitiveness combined with the drive to deliver innovative solutions to patients
- Interest in working cross-culturally with colleagues and study sites around the world
- Willingness to reduce ambiguity by obtaining necessary information to assist with making informed decisions



# Why did you select the Daiichi Sankyo GCSPV Fellowship Program?

#### GCSPV Current Fellow Perspectives



- Established presence in ADC development that enables the involvement of complex and impactful safety surveillance
- Strong company culture that fosters both professional growth and mental wellness
- Reputable mentorship tailored to enhance the fellows interests and experiences

#### Rayshion Nezy, Pharm.D.

First-Year Fellow, Clinical Safety & Pharmacovigilance

University of Arizona, R. Ken Coit College of Pharmacy



- Mid-sized company that has strong company culture and opportunities for visibility with leadership
- Contribute to the exciting ADC pipeline
- Play a role in ensuring patient safety

#### Dev Patel, Pharm.D.

First-Year Fellow, Clinical Safety & Pharmacovigilance

Rutgers University, Ernest Mario School of Pharmacy



- Exceptional commitment and integrity towards upholding patient safety in safety surveillance and risk management strategies
- Strong emphasis on effective cross-functional collaboration and communication
- Continual effort to enrich fellows' experience in areas of interest and introduce diverse opportunities to gain insight into other areas of the pharmaceutical industry

#### Cindy Nguyen, Pharm.D.

First-Year Fellow, Clinical Safety & Pharmacovigilance

UC San Francisco School of Pharmacy

#### GCSPV Fellowship Leadership Insights



GCSPV fellows contribute to ensuring the safe use of Daiichi Sankyo products

Department committed to fellows' professional development through guided mentorship

Fellows gain hands-on industry experience and contribute actively to safety projects

Collaborate cross-functionally to support proactive safety surveillance and risk management

Work closely to uphold quality and compliance throughout the product life cycle

United by the mission to put patients first through rigorous safety efforts

Lin Zhang, M.D., Ph.D.

Vice President, Clinical Safety & Pharmacovigilance



Unique opportunity to gain meaningful experience with strong preceptor and colleague support

Develop and enhance skills essential for a successful pharmaceutical industry career

Collaborate closely with cross-functional teams throughout the product life cycle

Proactively monitor and identify potential safety concerns in all product phases

Conduct safety evaluations and contribute to benefit-risk assessments and mitigation strategies

Maria Ellis, Pharm.D.

Executive Director, Clinical Safety & Pharmacovigilance | Preceptor



Novel and innovative approaches to investigate mechanisms of drug safety signals and patient risk profiles


Exposure to multiple aspects of drug development via cross-functional collaborations in drug safety research

Advancing improved patient outcomes through translational research

Develop critical analytical and problem-solving skills through hands-on experience

Zenta Tsuchihashi, Ph.D.

Executive Director, Clinical Safety & Pharmacovigilance | Preceptor







One, 2-Year Position

The Global Oncology Marketing Fellowship Program offers a unique opportunity for the Pharm.D. or Pharm.D. / M.B.A. fellow to gain valuable industry experience at a pharmaceutical company with a rich research history and a promising future of growth. This two-year program is designed to provide a comprehensive overview supporting compounds across the full spectrum of product development, but with an emphasis on oncology products, allowing hands-on opportunities, active coaching, mentoring and business analytics skill building. Our goal is to help provide the fellow with the tools necessary for highly successful marketing and market research careers in the pharmaceutical industry.

The core focus of the program will be on Daiichi Sankyo, Inc.'s internal pipeline for marketing and market research in oncology.





#### GOM Fellowship Activities & Experiences

#### Responsibilities

#### Primary responsibilities, which will be developed throughout the fellowship, include:

- Work with cross-functional and cross-regional business partners on the development of launch strategies
- Synthesizing competitive intelligence and market research findings
- Developing treatment and market evolution scenario plans
- Assessing the strength of early-stage pre-clinical and clinical trials
- Validating forecast assumptions and identifying key market drivers
- Integrating core drug development and market inputs into commercial value analysis

- Managing cross-functional projects involving internal and external stakeholders
- Creating product/brand messages in coordination with launch team positioning strategies
- Developing new market shaping tactics for products in the global Hematology & Rare Cancers portfolio
- Collaborating across functions to pull through cross-asset messaging externally at key congresses

#### Career Development

- Global product and market assessments
- R&D and new product strategy
- Global marketing, market shaping and messaging
- Pharmaceutical business analytics
- Clinical trial assessments
- Cross-functional management
- Global congress strategy
- One-on-one preceptor mentoring
- Professional training opportunities

#### FELLOWSHIP

#### Why did you select the Daiichi Sankyo GOM Fellowship Program?

#### GOM Current Fellow PERSPECTIVE



- Innovative work culture
- Career development
- Global impact

Shadi Dahduli, Pharm.D., R.Ph.

Second-Year Fellow, Global Oncology Marketing Rutgers University, Ernest Mario School of Pharmacy

#### GOM Fellowship Leadership Insights



Commitment to improving patient outcomes

Engage in cross-functional collaboration with R&D. Medical Affairs, and Value Access & Pricing

Strategic decision-making with a global, multi-regional lens

Create key deliverables contributing to brand strategy

Gain deep understanding of the oncology pharma landscape

Develop broad, impactful experiences at oncology innovator

#### Kenji Shiqeta, M.B.A.

Vice President, Global Oncology Marketing, Oncology Business Unit



Focus on both early and latestage drug development from a commercialization perspective

Develop commercialization strategies through collaboration with R&D. Medical Affairs. and Value & Access teams

Develop key deliverables that shape and strengthen the brand strategy

Gain deep understanding of the oncology pharma landscape

Develop broad, impactful experiences with an oncology leader dedicated to advancing patient care

#### Charles Fergusson, M.B.A.

Global Brand Leader, Oncology and Rare Disease | Preceptor





Two, 2-Year Positions

GOMA's mission is to transform the scientific evidence of the broad and innovative Daiichi Sankyo oncology portfolio to locally relevant clinical practice in all countries across the world. GOMA delivers high quality scientific and medical information and publications needed to educate and support healthcare professionals' treatment decisions, informing local and global treatment guidelines. GOMA supports our Research and Development colleagues by identifying evidence for potential new indications and sub-populations of interest. GOMA supports access submission efforts and educates patient organizations on the burden of the disease and its treatment options.

The goal of the program is to introduce the fellows to the breadth and depth of different GOMA activities and to gain hands-on experience working on deliverables.

Over the two years, fellows will gain broad exposure to different activities through rotation in four out of six areas within GOMA (approximately six months each). Fellows will work under the guidance of the respective function to gain experience delivering against the Medical Affairs plan and participate in strategic planning in:

- Publications
- Medical Content & Training
- Scientific Engagement

- Patient Advocacy
- Medical Strategy/Evidence Generation
   Clinical Operations

The GOMA Leadership Team will match the available areas for Year One and Year Two fellows with their interest and with an availability of a suitable project. This will allow the fellows to work on a project from its conception to the final delivery with support from a GOMA Director who is responsible for day-to-day operations of the respective area.



#### FELLOWSHIP

#### GOMA Fellowship Activities & Experiences

#### Responsibilities

The key responsibilities and projects vary depending on the GOMA area and include:

#### **Publications**

- Preparing and submitting a manuscript to a scientific journal
- Preparing and submitting an abstract to a global congress
- Preparing a poster or slides for an oral presentation for disclosure at a global congress

#### Medical Content & Training

- Generating Medical Information Guidance Documents
- Developing education materials and training events for internal knowledge and/or external reactive use
- Preparing medical materials for presentation and display at global congress booths

#### Scientific Engagement

- Planning, delivering and summarizing outcomes of an external advisory board (Medical Experts and/or Patient Advocacy Group Representatives)
- Coordinating KEE engagements at congresses
- Generating global insights reports

#### Clinical Operations

- Developing and executing interventional Phase IIIb/IV and non-interventional studies, medical access programs, and externally sponsored research
- Assisting with governance committees, drug supply management, sponsor oversight, and quality management

#### Patient Advocacy

- Delivering on patient-oriented activities
- Generating insights from the patient community
- Improving patient access to medicines through strategic projects
- Closing patient knowledge gaps on technology, health literacy, and clinical trials

#### Medical Strategy/Evidence Generation

- Assisting GOMA Team Lead with assessment of evidence gaps and unmet medical needs
- Planning activities to address the identified gaps
- Assisting in building Global Brand Plans: Situation Analysis, Strategic Imperatives and developing plans for Medical Affairs activities

#### Interactions

GOMA interacts on a daily basis with multiple internal and external stakeholders.

#### Key internal partner functions include:

- Regional Medical Affairs
- Global Research and Development
- Global Marketing
- Global Market Access and Pricing
- Global Clinical Safety and Pharmacovigilance
- Legal
- Regulatory Affairs
- Corporate Communications

#### Key external partners include:

- Global Key External Experts
- Healthcare Professionals (physicians, nurses, pharmacists)
- Patient Advocacy Groups representing patients in different countries and regions of the world
- Health Authorities (FDA, CHMP/ EMA, PMDA)
- Medical Societies (ASCO, ESMO, ASH, EHA)

During the participation in the program the fellows will be encouraged and expected to participate in all interactions with internal and external GOMA stakeholders alongside the other GOMA Team members

#### Requirements

#### It is expected that fellows will have:

- An interest in oncology through participation in prior research projects, internships, clinical rotations, etc.
- A scientific curiosity and willingness to navigate the complexities of oncology drug development from early clinical stages to launch in different countries around the world
- Ability to synthesize their knowledge and present in a clear and concise manner when interacting on a daily basis with different GOMA stakeholders

#### PHARM.D. FELLOWSHIP

#### Why did you select the Daiichi Sankyo GOMA Fellowship Program?



#### GOMA Current Fellow Perspectives



- Custom rotations to fit career goals
- Structured mentorship programs
- Emphasis on crossfunctional collaboration

#### Chyan Decker, Pharm.D.

Second-Year Fellow, Global Oncology Medical Affairs

University of Iowa College of Pharmacy



- Leader in oncology therapeutics
- Commitment to healthy work culture
- Supportive mentorship and comprehensive rotations

#### Sophie Wei, Pharm.D., R.Ph.

Second-Year Fellow, Global Oncology Medical Affairs

Rutgers University, Ernest Mario School of Pharmacy



- Focused on advancing patient-centric solutions
- Collaborative environment supports innovative and robust oncology pipeline
- Strong emphasis on maximizing opportunities and visibility for fellows

#### Sinduja Sivakumar, Pharm.D.

First-Year Fellow, Global Oncology Medical Affairs

Rutgers University, Ernest Mario School of Pharmacy



- Steadfast investment in the personal and professional development of fellows
- Integrity-driven leadership that keeps patients at forefront of oncology care
- Impactful collaboration that drives worldwide oncology excellence

#### Stacey Velasco, Pharm.D., M.B.A.

First-Year Fellow, Global Oncology Medical Affairs

Temple University School of Pharmacy

#### GOMA Fellowship Leadership Insights



Consistent fellow success in pharmaceutical industry

Exposure to various functional areas

Opportunities for crossdepartmental contributions

Diversified industry experience

Enhanced retention through rotational training

Thomas Malieckal, Pharm.D., R.Ph.

Vice President, Medical Capabilities, Global Oncology Medical Affairs | Preceptor



Fellowship Leadership Committee as a source of guidance and executive support

Balance of mentorship and business opportunity alignment

Focus on fellow advocacy and career inspiration

Emphasis on aligning opportunities with individual interests

Guided by the spirit of giving and leadership

#### Giselle Cortez

Associate Director, Clinical Trial Management, Resources and Operations, Global Oncology Medical Affairs



Industry-leading fellowship program focused on Medical Affairs careers

Strategic positioning for success in the biopharmaceutical industry

Diverse rotational experiences across key Medical Affairs functions

Strong foundation in core competencies

Tailored rotations based on individual professional interests

Donato S. Forlenza, Pharm.D., R.Ph.

Associate Director, Medical Content & Training Lead, Global Oncology Medical Affairs



Unique opportunity to gain broad medical affairs exposure

Hands-on experience in publications, medical content/ training, scientific engagement, strategy, and patient advocacy

Strong foundation for a successful medical affairs career

Continued growth through learning from colleagues and mentors

Foundation for fellows to grow into future medical affairs leaders

#### Carolyn Federici, Ph.D.

Director, Indication Strategy Lead, Global Oncology Medical Affairs







One, 2-Year Position

The GRLS Fellowship is a distinguished program designed to immerse fellows in the intricacies of global pharmaceutical labeling and regulatory affairs. It provides a unique opportunity to gain firsthand experience in developing and implementing labeling strategies that meet global regulatory requirements and support global drug development with a primary focus on the rapidly expanding therapeutic area of oncology. The fellow will collaborate with cross-functional teams, including regulatory affairs, clinical development, pharmacovigilance, marketing, and other stakeholders to ensure that labeling accurately reflects the safety, efficacy, and non-safety sections of pharmaceutical products. The fellow will also have the unique opportunity to make significant contributions to the development of labeling on portfolio products. This program provides in-depth training on developing effective labeling strategies to navigate complex challenges while aligning with the diverse regulatory requirements of key global markets.

During the two-year program, the fellow will engage in hands-on projects, trainings/conferences, and mentorship from industry leaders, fostering a deep understanding of the strategic role labeling plays in the lifecycle of drug products. The fellow will also have the opportunity to leverage their prior Pharm.D. knowledge to enhance their learning experience and contribute meaningfully to labeling initiatives. By the end of the fellowship, the fellow will have developed a robust foundation in global labeling practices, preparing them for future leadership roles in the pharmaceutical industry, equipped with the knowledge and skills to drive innovation and excellence in drug development.





#### GRLS Fellowship Activities & Experiences

#### Responsibilities

#### Year One:

Foundation Building and Skill Development

#### Regulatory Affairs Exposure

- Building a thorough understanding of labeling regulations and their practical application in the creation of product labels
- Gain in-depth knowledge of the core labeling documents. United States Prescribing Information (USPI). and EU Summary of Product Characteristics (SmPC), as well as the key differences
- Develop an understanding of existing oncology labeling precedence in the US, EU, and other major markets
- Learn about the processes and requirements for regulatory submissions and approvals

#### Collaborative **Projects**

- Work alongside cross-functional teams to understand the interdisciplinary nature of labeling
- Assist in drafting and reviewing labeling documents. ensuring compliance with regulatory standards and applicable guidances
- Utilize tools and resources to perform competitor analyses, gathering and assessing relevant labeling information to support labeling decisions
- Support the Global Labeling Strategy Lead (GLSL) to identify and document country labeling differences

#### **Understanding Labeling** Operations/Life cycle

- Develop a comprehensive understanding of labeling operations, including creation, review, and approval processes
- Understand the labeling life cycle from initial development to post market updates, recognizing the importance of accuracy and compliance in each stage
- Learn how to efficiently use and navigate the electronic document management systems

#### Year Two: Advanced Responsibilities and Leadership Development

#### Strategic **Labeling Projects**

- Lead projects focused on developing and implementing labelina strategies for new or existing projects
- Collaborate with alobal teams to address complex labeling challenges and ensure alignment with international regulatory requirements
- Gain hands-on experience in the creation of a Target Product Label (TPL) to support the early drug development proces

#### Regulatory **Submissions**

- Prepare and submit labeling documents for regulatory approval. gaining hands-on experience in the Health Authority (HA) submission process
- HA queries and feedback from regulatory authorities. demonstrating problem solving and adaptability

- Respond to

#### Innovation and **Improvements**

- Aid in the enhancement of labeling process by actively contributing insights to refine process documents. including job aids, work instructions. and playbooks

#### Requirements

#### It is expected that fellows will have:

- Ability to pay attention to detail and to manage complex information
- Knowledge of the drug development process and life cycle management
- Effective collaborative skills
- Scientific and critical thinking skills
- Strong analytical and problem-solving skills

#### GRLS Fellowship Leadership Team



Unique opportunity to contribute to the drug development and lifecycle management of product labeling

Apply clinical and regulatory knowledge to the creation and refinement of global labeling documents

Collaborate closely with teams across clinical, regulatory, and commercial functions

Develop expertise in global labeling strategy and regulatory requirements

Benefit from Daiichi Sankyo's supportive, growth-oriented culture

Build a strong foundation for long-term success in the pharmaceutical industry

#### Mario Ibrahim, Pharm D.

Associate Director, Global Labeling Strategy | Preceptor



Hands-on experience developing global labeling strategies for products at various life cycle stages

Develop labels optimized for patients, healthcare providers, and regulators

Mentorship from experienced labeling strategists and operations professionals

Build core skills in regulatory strategy, communication, and teamwork

Expand professional network across drug development disciplines

#### Vijay Sammeta, M.D., M.B.A.

Head of Global Regulatory Affairs Labeling







## U.S. Marketing (USM) Fellowship

Two, 2-Year U.S. Marketing Position

U.S. Marketing is the engine that drives strategies and tactics to help get our medicines to metastatic breast cancer (mBC) patients in need. Fundamental to this fellowship will be working cross-functionally to support approved products and/or prepare for upcoming launches. The work will be in breast or lung cancer and support the success of the brand. The fellow will have the opportunity to participate in the development of key resources and partner with a variety of stakeholders to ensure we execute with excellence and deliver for our patients.



#### U.S. Marketing Fellowship Activities & Experiences

#### Responsibilities

Fellows will receive one-on-one preceptor mentoring and a number of opportunities to undertake U.S. Marketing activities, including:

#### U.S. Marketing

- Work with cross-functional business partners on the development and execution of promotional resources
- Help develop personal and non-personal promotion tactics that support brand strategy and are executable by customer facing teams
- Present to various internal management committees and groups
- Help oversee various agency relationships
- Manage productive and timely communication with all external agency partners

#### Interactions

It is expected that fellows will interact with other commercial functions including:

- Insights and Analytics
- U.S. Medical Affairs
- U.S. Market Access
- Finance
- Sales Training
- Marketing
- Sales
- Data Governance
- IT
- Alliance Partners (as needed)

#### Requirements

It is expected that fellows will have:

- Critical thinking
- Creativity
- Highly motivated
- Intellectual curiosity
- Strong oral and written communication skills
- Organized and responsible
- Keen to work with individuals from diverse backgrounds





#### Why did you select the Daiichi Sankyo USM Fellowship Program?



#### U.S. Marketing Current Fellow Perspectives



- Passionate, driven, and meaningful mentorship and team dynamic
- Innovative pipeline and global impact
- Compassion for patients

#### Aryanna Ilamni, Pharm.D.

Second-Year Fellow, U.S. Marketing Rutgers University, Ernest Mario School of Pharmacy



- Leaders in the marketplace with innovative and science-driven therapies that are transforming care
- Marketing strategies that embrace evolving trends and reflect a deep commitment to patient care
- A culture that actively demonstrates its values through growth and development of fellows

#### Rohit Marwah, Pharm.D.

First-Year Fellow, U.S. Omnichannel Marketing University of Pittsburgh School of Pharmacy



- Seamless marketing driving brand growth through strategic initiatives
- Strong commitment to innovation and patient care
- Environment focused on growth and meaningful impact

#### Hanna Song, Pharm.D.

First-Year Fellow, U.S. Omnichannel Marketing St. John's University College of Pharmacy and Health Sciences

FELLO SHIP

# USM Fellowship Leadership Insights



Integrated member of designated U.S. Marketing team

Make direct contributions to advancing U.S. Marketing projects

Two-year immersive program designed to develop practical marketing skills, industry knowledge, and strategic thinking

Builds a strong foundation for a career in pharmaceutical Marketing

Kara Reheis, M.B.A.

Vice President, U.S. Marketing



Opportunity to make a broad patient impact across high unmet-need breast cancer areas

Support ongoing indications while contributing to strategic planning for upcoming launches

Opportunity to engage in multiple phases of product lifecycle from current market support to future commercialization

Karen Kopp, Ph.D.

Director U.S. Marketing | Preceptor




Participate in launch planning and development of key resources

Collaborate with diverse stakeholders to ensure successful execution

Help deliver innovative therapies that address critical patient needs in high unmet need areas

#### **Bethany Sardinha**

Senior Director US Marketing | Preceptor



Daiichi Sankyo's USM Fellowship Program provides fellows with...





# U.S. Medical Affairs (USMA) Fellowship

One, 2-Year Position

The goal of the two-year USMA Fellowship Program is to provide real-world, hands-on experience in oncology across traditional functional areas of a Medical Affairs Department.

The USMA leadership will work with the fellow to concentrate their time in a specific functional area based on personal interest, experience, and the business opportunities of the Company. The fellow will have the opportunity to work on projects across several functional areas within Medical Affairs.

Over the two-year fellowship, the fellow will gain broad exposure to different functions within the USMA department, including:

- Medical Research & Strategy
- Medical Information
- Medical Affairs Operations
- Medical Review & Clearance
- Independent Medical Education



# USMA Fellowship Activities & Experiences

#### Responsibilities

The key responsibilities and projects vary depending on the USMA area and include:

#### Medical Research & Strategy

- Assisting in coordination and planning of advisory board meetings
- Supporting medical training of the sales team and field medical team
- Collaborating with field medical teams to help convey critical insights back to the home office
- Working with vendors on medical slide development and review, as well as scientific communication efforts and disseminating information internally
- Assisting in strategic congress planning and coordination with key internal stakeholders on medical affairs activities
- Contributing to medical and scientific competitive intelligence monitoring and reporting

#### Medical Information

- Creating, updating and reviewing medical response documents to unsolicited medical inquiries
- Building knowledge and understanding of how the MI contact center operates
- Assisting in strategic planning from an MI perspective

#### **Medical Affairs Operations**

- Supporting the generation, synthesis, and alignment of key medical insights from across USMA functions to inform strategic decision-making and drive cross-functional collaboration
- Acting as liaison to functional areas outside of USMA (i.e., Business Operations, etc.) to understand key business insights and translate implications for USMA stakeholders
- Facilitating the development and adoption of new technologies that align with long-term digital innovation strategies
- Overseeing USMA key performance indicators. providing comprehensive reporting to track progress, measure impact, and support data-driven decision-making in alignment with reporting plans developed collaboratively with Field Medical Affairs. Medical Research & Strategy, as well as Medical Leadership

#### Medical Review & Clearance

- Learning to conduct comprehensive medical reviews and serving as a scientific resource for the Promotional Material Review Team and Programs and Grants Committee (PGC)
- Assisting in review of other scientific assets such as medical slide decks and internal training materials
- Understanding what governs PGC and the types of activities submitted from cross functional partners

#### Independent Medical Education:

- Increasing awareness related to industry's role in supporting external/independent medical education (IME), gaining exposure to strategies and the process for supported tactics
- Developing a foundation on reviewing IME grants, communicating with providers, and collecting, analyzing and communicating outcomes
- Observing IME at major symposia and digitally based IME activities and reviewing/sharing outcomes to internal stakeholders

#### Interactions


USMA interacts on a daily basis with multiple internal and external stakeholders.

#### Key internal partner functions include:

- Field Medical Affairs
- Health Economics & Outcomes Research
- Marketing
- Medical and Sales Training
- Global Medical Affairs
- Pricing & Access
- Clinical Operations
- Clinical Development
- Legal Affairs
- Public Affairs

# FELLOWSHIP

# Why did you select the Daiichi Sankyo USMA Fellowship Program?



## USMA Current Fellow Perspectives



- Expanding pipeline with numerous opportunities
- Visibility to senior leadership
- Impactful contributions early in career

#### Matthew Armanus, Pharm.D., M.B.A., R.Ph.

Second-Year Fellow, Medical Research & Strategy, U.S. Medical Affairs

University of Rhode Island College of Pharmacy



- Strong interand intra-team relationships
- Track record of developing equipped fellows
- Visibility within the company

#### Ethan Lim, Pharm.D.

Second-Year Fellow, Medical Information & Education, U.S. Medical Affairs

Rutgers University, Ernest Mario School of Pharmacy



- Robust mentorship culture and meaningful oncology pipeline
- Opportunity to bridge clinical evidence with strategic impact
- Value the flexibility and depth of experience offered

#### John Rizk, Pharm.D.

First-Year Fellow, U.S. Medical Affairs D'Youville University School of Pharmacy

# USMA Fellowship Leadership Team



Well-established, respected Medical Affairs Fellowship Program

Strong support from Medical Affairs Leadership Team

Extensive network of fellowship alumni across the organization

Leadership team guides each fellow's development plan

Focus on personal growth and professional progress

Coordinated support ensures fellow success during and beyond the program

Kaley Lugo, Pharm.D., M.B.A.

Associate Director, Medical Review, Medical Information & Education, Oncology | Preceptor



Unique opportunity to explore various Medical Affairs functions

Collaboration with cross-functional teams (Global MA, Marketing, Training)

Versatile program structure supports broad skill development

Builds strong professional network

Prepares fellows for successful careers in Medical Affairs

Bridgette Leclair, Pharm.D.

Associate Direction, U.S. Medical Affairs | Preceptor







# U.S. Oncology Business Division Training & Development (OBD T&D) Fellowship

One, 2-Year Position

The U.S. OBD Training & Development Fellowship Program offers a unique opportunity for the Pharm.D. or Pharm.D./M.B.A. fellow to gain real-world and practical hands-on experience in a dynamic and fast-paced department. The OBD Training and Development Department includes five key teams: Commercial Sales Training, Medical Affairs Training, Market Access Training, Operations and Leadership Development. The department's mission is to deliver first-in-class training solutions and execute product imperatives to sustain a competitive advantage in the oncology and supportive care marketplace.

The aim of the OBD Training & Development Fellowship Program is to provide Pharm.D. fellows with a range of experiences collaborating on a variety of OBD Training and Development deliverables. In Year One (Rotational Year), fellows will rotate through three core teams (Medical Affairs Training, Market Access Training and Field Sales Training) with an opportunity for longitudinal or stretch projects with Operations and Leadership Development. The fellow will work under the guidance of the respective Director in each area. During Year Two (Elective Year), the fellow will work with the Program Preceptor to develop an individual development plan focused on areas of their interest in a maximum of three areas. Business opportunities and fellow interest permitting, a field sales and/or marketing rotation may be included as part of the fellowship.



# OBD T&D Fellowship Activities & Experiences

#### Responsibilities

OBD Training & Development Fellows will rotate through multiple roles in the department including Field Sales Training, Medical Affairs Training and Market Access Training with exposure to Leadership Development and Operations

#### Field Sales, Medical Affairs and Market Access Training Rotation

- Enhance understanding of the Learning & Development strategy and activities for the commercial. market access, and medical field-facing teams to include:
- Cross-functional collaboration with internal partners (e.g., Marketing, Home Office Medical Affairs) to understand training needs and identify innovative training solutions for all aspects of training
- Leverage clinical expertise in the development of training materials, including foundational modules. competitive marketplace events, and regional and national sales meeting workshop content

#### Rotation Agnostic

- Execute delivery of training solutions through various communication channels and events including virtual and live training events
- Support the development of annual training plans
- Attend various medical/scientific meetings and national sales meetings
- Cross-collaborate within all aspects of the OBD to identify leadership and skill development needs
- Learn business operation systems that help support OBD and customer-facing teams
- Support the facilitation of leadership development trainings

#### Interactions

In addition to Commercial Training and Development Team, it is expected fellows will interact with other internal commercial functions including:

#### Internal

- Global & U.S. Medical Affairs
- Global & U.S. Market Access
- Global & U.S. Marketing
- OBD European Union
- Legal & Medical Reviewers
- Field Medical Affairs
- Commercial Sales Force
- Corporate Communications
- Human Resources
- Corporate Leadership Development

#### External

- Alliance Partners
- Key External Experts and
- Healthcare Professionals
- Patients & Patient Advocacy Groups

Depending on interest, fellows may also interact with the following external stakeholders:

- Healthcare Professionals
- Agency Partners
- Patients

#### Requirements

It is expected that fellows should possess the following skills:

- Organized and Dependable
- Strong oral and written communication skills
- Innovative Thinkers
- Ability to be flexible
- Highly Motivated
- Open and Approachable
- Self-Motivated
- Ability to work independently and collaboratively with others



# Why did you select the Daiichi Sankyo OBD T&D Fellowship Program?



# OBD T&D Current Fellow PERSPECTIVES



- Comprehensive and valuable hands-on training opportunities
- Development of strategic training plans and initiatives for impactful healthcare delivery
- Leaders and mentors invested in professional development and growth

#### Amanda Lin, Pharm.D.

Second-Year Fellow, Oncology Business Division Training & Development

University of Rhode Island College of Pharmacy



- Culture that prioritizes learning, growth, and mentorship
- Pipeline focused on advancing oncology
- Opportunities to contribute to crossfunctional initiatives and partnerships

#### Sophia Edgecombe, Pharm.D.

First-Year Fellow, Oncology Business Division Training & Development

University of Kentucky College of Pharmacy

# OBD T&D Fellowship Leadership Insights



Engages fellows with clinical, operational, interpersonal, and commercialization experiences

Partners with diverse customers across multiple roles and responsibilities

Offers unique, varied work and development opportunities exclusive to the Training & Development Department

Develops high-potential associates for long-term growth and careers at Daiichi Sankyo

Belief that extraordinary people, culture, and innovative therapies combine to benefit patients

#### Ryan Hansen

Executive Director, Commercial
Training and Development | Preceptor



Unique opportunity to join a cross-functional, matrixed team engaging across the organization

Energetic and innovative environment focused on therapeutic knowledge and leadership development

Provides foundational skills essential for a successful career

Opportunities to build relationships and collaborate with commercial and medical partners

Exposure to both U.S. and global teams for broad professional development

Jamie Jolly, Pharm.D.

Director, USMA Training and Development



Fellowship offers rare chance to follow DSI assets from study start through commercialization and life cycle management

Focus on training and development perspective throughout the asset journey


Learn how cross-functional teams collaborate to design impactful learning journeys

Personalized experience in the second year by selecting a focus area aligned with career goals

Program essential for cultivating future leaders in pharma

#### Samantha Breckenridge, Pharm.D.

Associate Director, USMA Training and Development





# Non-Recruiting FELLOWSHIPS

Companion Diagnostics (CDx)	47
Global Business Development (GBD) Transactions & Marketing	48
Global Oncology Value, Access & Pricing (GOVAP)	49
Global Regulatory Affairs (GRA)	
Pharmacoepidemiology (PE)	51
Quality Assurance Good Manufacturing Practices (QA GMP)	52
Quantitative Clinical Pharmacology (QCP)	53
Translational Science (TS)	54

WHY DAIICHI SANKYO?

# Companion Diagnostics (CDx) Fellowship

The mission of the Companion Diagnostics (CDx) Department in Global Oncology R&D is to make Precision Medicine a reality for patients. Our teams lead the co-development of companion diagnostics tests in parallel with the corresponding drug and in close collaboration with our external in vitro diagnostic partners. These tests can identify patients most likely to benefit from our therapies, can identify those patients at risk for side effects and can monitor treatment responses.

Precision Medicine is a growing field, and it is an increasingly important enabler for bringing innovative therapies to our patients. The goal of the two-year fellowship is to provide the fellow with experience in creation and oversight of CDx development strategies and in participating in activities for regulatory submission, approval and launch of CDx tests with our drugs.

# GDx Current Fellow Perspectives



- Leader in precision medicine
- Expanding pipeline with numerous opportunities
- Preceptors who promote future career goals

#### Sophia Ventrano, Pharm.D.

Second-Year Fellow. Companion Diagnostics

Binghamton University School of Pharmacy



- Leader in ADCs and personalized medicine
- Advancing precision oncology via companion diagnostics
- Empowering patientcentric solutions

#### Feifei Jia, Pharm.D.

First-Year Fellow. **CompanionDiagnostics** 

St. John Fisher University, Wegmans School of Pharmacy



# Global Business Development (GBD) Transactions & Marketing Fellowship

The Global Business Development Fellowship Program offers a unique opportunity for the Pharm.D. or Pharm.D. / M.B.A. fellow to gain valuable industry experience at a pharmaceutical company with a rich research history and a promising future of growth.

The core focus of the program will be on business development opportunities and marketing across therapeutic areas, with an emphasis on oncology.

This two-year program is designed to provide hands-on opportunities with the Transactions and Marketing teams, together with active coaching and mentoring. Our goal is to help provide the fellow with the tools necessary for highly successful business development and marketing careers in the pharmaceutical industry.

# GBD Current Fellow PERSPECTIVES



- Legacy of mentorship and success
- Cross-functional Collaboration
- Interface with innovative leaders

#### Caroline Culpepper, Pharm.D.

Second-Year Fellow. Global Business Development

The University of Tennessee Health Science Center, College of Pharmacy



- Recognized leader in the ADC space
- Pipeline reflects a clear focus on moving the needle in cancer therapies
- Committment to professional growth through mentorship, leadership support, and access to high-impact opportunities
- GBD offers a dynamic space, bridging science and strategy to drive impactful deals

#### Alicia Ngo, Pharm.D.

First-Year Fellow, Global Business Development Purdue University, College of Pharmacy

A

WHY DAIICHI SANKYO?

# Global Oncology Value, Access & Pricing (GOVAP) Fellowship

The GOVAP department is responsible for leading, developing and continually enhancing our value propositions to ensure optimal pricing and reimbursement for Daiichi Sankyo oncology products. The GOVAP fellowship offers a unique opportunity to gain experience and exposure to pharmaceutical market access. The two-year global program will offer a comprehensive and hands-on experience of reimbursement and payer strategy, supporting both in line and pipeline oncology products. This fellowship will provide the opportunity to partner with internal and external stakeholders to ensure market access strategy and tactics are aligned and localized. Our objective is to develop a specialized skill set to excel in global pricing & access careers in the pharmaceutical industry.

# GOVAP Current Fellow Perspectives



- Patient-centric values
- Individual fellowship experience
- Opportunity to work in alliance setting

#### Sabrina Wang, Pharm.D.

Second-Year Fellow, Global Oncology HEOR and RWE University of Maryland School of Pharmacy



- Strong global presence and cutting-edge oncology pipeline
- Meaningful contribution to HEOR & RWE research and projects
- Positive company culture to nurture professional development

#### Carsyn Norway, Pharm.D.

First-Year Fellow, Global Oncology HEOR and RWE Rutgers University, Ernest Mario School of Pharmacy



- Strong leadership in global market access for innovative oncology therapies
- Bridge clinical evidence, policy, and real-world market needs
- Build expertise in pricing, reimbursement, and HTA strategy

#### Bhumika Devnani, Pharm.D., R.Ph.

First-Year Fellow, Global Oncology PRA University of Wisconsin-Madison School of Pharmacy

# Global Regulatory Affairs (GRA) Fellowship

The GRA R&D Fellowship Program offers the opportunity to acquire first-hand working knowledge of the regulatory requirements for global drug development and the conduct of clinical studies. Using this knowledge, the fellowship also offers the opportunity to develop the necessary skill set to provide scientifically driven, tactical and strategic regulatory guidance to cross-functional project teams.

Included within the Daiichi Sankyo oncology franchise are the cutting-edge Antibody Drug Conjugate (ADC) compounds being developed using unique approaches to address the unmet medical needs of patients.

During this two-year program, the fellow will collaborate closely with colleagues and scientists representing diverse backgrounds, knowledge, and expertise, both within regulatory and across other functions, e.g. Clinical Development, Clinical Pharmacology, Biostatistics, Drug Safety, Translational Medicine, and Marketing.

## GRA Current Fellow Perspectives



- Supportive work environment and eager to teach mentors
- Having the opportunity to contribute to innovative projects within the oncology therapeutic area

#### Sara Blodgett, Pharm.D.

Second-Year Fellow, Global Regulatory Affairs University of Michigan College of Pharmacy



- Passionate team focused on developing their fellows
- Opportunity to be involved in the research of impactful oncology medications
- Innovative and collaborative environment focused on patient-centered solutions

#### Peter Gordinier, Pharm.D.

First-Year Fellow, Global Regulatory Affairs University of Connecticut School of Pharmacy

WHY DAIICHI SANKYO?



# Pharmacoepidemiology (PE) Fellowship

The PE Fellowship Program is an initiative between Daiichi Sankyo, Inc., and the Rutgers Center for Pharmacoepidemiology and Treatment Science focused on the evaluation of the use and outcomes of drugs in populations. This is a two-year fellowship program in PE that provides didactic education as a core part of training that enables real-world, practical, hands-on experience for Pharm.D. fellows who want to become independent and successful practitioners in the pharmaceutical industry.

The aim of the PE Fellowship Program is to provide the necessary research skills to conduct PE research for a career in the pharmaceutical industry. The fellow will develop a greater understanding of the role of PE in drug development and will contribute to the interpretation of real-world data. Pharmaceutical industry preceptors will contribute to the professional development of the fellow.

# PE Current Fellow PERSPECTIVES



- Ambitious company goals
- Immersive work experiences
- Commitment to professional development

Rachel Clark, Pharm.D.

Second-Year Fellow, Pharmacoepidemiology University of North Texas Health Science Center



# Quality Assurance Good Manufacturing Practices (QA GMP) Fellowship

The Daiichi Sankyo QA GMP Fellowship Program offers a unique opportunity for the Pharm.D. fellow to gain valuable industry experience in the quality assurance department at a pharmaceutical company with a rich history and a promising future in the oncology therapeutic area. It will provide the fellow a holistic understanding about the delivery of high-quality medicines from development to commercial phases.

This two-year program is designed to provide a comprehensive overview of the quality assurance organization supporting both commercial and investigational medicinal products. The QA GMP fellow will have a unique opportunity for a blend of hands-on and supportive roles in the six groups comprising QA GMP namely Strategy, Compliance, Quality Management Systems, Pharma Product, External Supplier and Audit.

The aim of the QA GMP Fellowship is to provide an opportunity to learn the skills required for a successful career in the quality assurance department of a global pharmaceutical company by ensuring the application of good manufacturing practices to support the quality of Daiichi Sankyo products supplied globally to patients.

# QA GMP Current Fellow Perspectives



- Commitment to patient safety by ensuring the highest standards of quality and compliance
- Expertise in complex supply chain dynamics for ADCs and innovative global pipeline
- Cultivation of professional growth through cross-functional & international collaboration

Eun Sik (John) Cho, Pharm.D., R.Ph.

First-Year Fellow, Global QA GMP Rutgers University, Ernest Mario School of Pharmacy



WHY DAIICHI SANKYO?



# Quantitative Clinical Pharmacology (QCP) Fellowship

QCP's mission is to quantitatively integrate non-clinical, biomarker, and clinical data. This data integration is performed to inform optimal dosing schedules, identify appropriate patient populations, determine proper monitoring parameters and maximize the therapeutic benefit of our medicines. To achieve our mission, QCP is committed to incorporating model-based approaches in our drug development programs. The use of modeling and simulation in drug development helps modernize and improve the efficiency of drug delivery to patients. Model-based or model-informed drug development (MBDD), a type of drug development paradigm, facilitates quantitative decisionmaking throughout the drug development continuum. MBDD helps translate information between non-clinical and clinical settings to inform discovery, aids in the selection of doses and dosing regimens, provides information to assess risks vs outcomes to progress at various development checkpoints and provides supportive clinical evidence of medicines following registrational studies.

## QCP Current Fellow Perspectives



- Supportive mentorship and environment fostering teamwork and growth
- Opportunity to learn new skills

April Zhou, Pharm.D.
Second-Year Fellow,
Quantitative Clinical Pharmacology
UC San Francisco School
of Pharmacy



- Track record of innovation and global impact
- Alignment with professional goals and values

Elise Vo, Pharm.D.

Second-Year Fellow,
Quantitative Systems Pharmacology
University of North Texas
Health Science Center

WHY DAIICHI SANKYO?

# Translational Science (TS) Fellowship

The mission of Translational Science (TS) is to define and implement translational strategies and state-of-the-art biomarker technology platforms to enable successful drug development. TS delivers key translational data that contributes to clinical development strategies (forward translation) and pre-clinical opportunities for new targets and combinations (reverse translation). Our objectives are to inform dose selection and regimen through assessment of pharmacodynamic biomarkers, characterize drug mechanism of action, identify optimal target populations, devise and test hypotheses for patient selection, resistance mechanisms and combination strategies, and identify candidate biomarkers for Companion Diagnostics (CDx) development.

# TS Current Fellow Perspectives



- Core value of patientcentered approach
- Opportunity to grow soft skills and professional expertise
- Contribution to research and improving patient outcomes

#### Anh Huynh, Pharm.D.

Second-Year Fellow, Translational Biomarkers Mercer University College of Pharmacy



- Dedication to improving patient outcomes through innovative science
- Exciting opportunities to make meaningful contributions to oncology drug development
- Supportive culture that fosters professional growth and development

#### Rong Xin Liu, Pharm.D.

First-Year Fellow, Translational Science Early Oncology University of Kansas School of Pharmacy







Ernest Mario School of Pharmacy (EMSOP) Rutgers, The State University of New Jersey





# Soaring Ever Higher

# Rutgers Pharmaceutical Industry Fellowship (RPIF) Program

Ernest Mario School of Pharmacy (EMSOP)
Rutgers, The State University of New Jersey

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor of EMSOP, Dr. Carolyn Seyss, the Executive Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as the Director Emeritus.



Joseph A. Barone, PharmD, FCCP Dean and Distinguished Professor



**Carolyn Seyss, PharmD, RUCIF** Fellowship Executive Director



Michael Toscani, PharmD Research Professor, Fellowship Director Emeritus

#### **Program History**

1984

EMSOP and 2 pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically- trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the RPIF Program grew significantly and expanded to now include 29 companies within the pharmaceutical and biopharmaceutical industry with over 300 Fellows.

2002

Dr. Ernest Mario generously provided an endowment to establish RPIF as an Institute to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- Create the Fellowship structure, providing strategic leadership and administrative support
- Promote quality, communication, scholarly activity, and professional development
- Arrange specialized training opportunities within the pharmaceutical and biopharmaceutical industry

2018

RPIF expanded to offer interdisciplinary Fellows' training by adding physician Fellowship opportunities to our well-established program.

2023

The RPIF Certificate is recognized with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow).** 

Well over 1,800 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program.

Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.

#### **Professional Development Series**

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the sponsor companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

#### **Key Program Features**

RPIF FOSTERs the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through:



#### Family of Leading Companies

Partners include several top global pharmaceutical/biopharmaceutical companies and offer large to small company environments.



#### Outstanding Alumni Track Record

Well over 1,800 alumni hold prominent positions at many leading companies, including VP and C-suite levels.



#### Strong Network

Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.



#### Trusted and Proven Since 1984

The Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry, developing foundations for future leaders.



#### **E**nhanced Career Development

Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.



#### **R**igorous Academic Component

Rutgers affiliation provides academic and professional development opportunities.

Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Rutgers, The State University of New Jersey is one of the major state university systems in the United States. EMSOP is part of Rutgers Health and is the only state school of pharmacy in New Jersey. EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey.

While RPIF offers all the benefits of a large program with an extensive network of distinguished professionals, Fellows receive the individual attention of a small program where they are known and supported as individuals.

#### **Application Process and Eligibility Requirements**

Pharmacy Fellows for the RPIF Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy from an ACPE-accredited institution before July 1 of the fellowship term.

#### **HOW TO APPLY:**

The RPIF Program is highly competitive. Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as October 8, 2025 by visiting our website at: https://pharmafellows.rutgers.edu/how-to-apply/

All application materials must be submitted electronically to the RPIF website per instructions on the site.

REQUIRED ITEMS:	SUBMIT BY:
Application with short-answer questions	October 17th
Letter of Intent (LOI)	October 17th
Curriculum Vitae (CV)	October 17th
Letters of Recommendation (LORs)	December 1st

#### **ADDRESS LOI AND LORs TO:**

Joseph A. Barone, PharmD, FCCP
Dean and Distinguished Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020







"The RPIF Program hasn't just opened doors. It has changed the way I walk through them—more grounded in where I stand and more intentional in how I move forward. It has given me the opportunity to use my PharmD education to serve patients in new ways, shaping the conversations and decisions that impact their care. It has given me the confidence to speak up, the space to grow, and the kind of mentorship that sees your potential before you do. If you're ready to take the next step toward a career in the pharmaceutical industry, let RPIF be where your journey begins."

Pooja Singh, PharmD, Global Regulatory Affairs and Global Value & Access Fellow **RPIF Chief Fellow** 



Olivia Violette, PharmD Global Medical Information Fellow **RPIF Chief Fellow** 

Connect with us on social media: @RutgersFellow



"Being a Rutgers Fellow has been such a pivotal part of my professional story, truly exceeding my expectations. This journey has transformed my leadership skills, giving me the confidence and tools I know I'll use every day. I'm grateful to be part of this community!"

Ginika Nwokeabia, PharmD USMA/Medical Science Liaison - Neuroimmunology Fellow **RPIF Chief Fellow** 



#### **Aligned First Offer Date** December 12, 2025

The choice of a Post-Doctoral Industry Fellowship is an important decision. AIFA exists to promote a consensus first offer date for all Fellowship positions. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship.

We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this AIFA-aligned offer date. Candidates should feel free to request an extension for any earlier offer to allow them to consider their options.







#### U.S. Corporate Headquarters

Daiichi Sankyo, Inc. 211 Mount Airy Road Basking Ridge, NJ 07920 Phone: +1 908 992 6400 DaiichiSankyo.us

















